Drug DevelopmentAzetukalner showed a rapid onset and durable reduction in seizure burden, with a 35% placebo-adjusted reduction in seizure frequency, suggesting at minimum non-inferior efficacy compared to commonly prescribed ASMs.
Financial PositionThe company ended the quarter with approximately $625 million in cash, which management believes should fund operations into 2027.
Market PositionAzetukalner will be nicely positioned to capture significant share as a second-line therapy given its efficacy, mood benefits, and ease-of-use, in contrast to first-line therapies with mood liabilities.